Using a constructed ANN model, researchers sought to predict the long-term outcomes of microvascular decompression surgery and the factors that influence prognosis in patients with trigeminal neuralgia.
The researchers’ goal was to provide the initial evidence for the safety and efficacy of sublingual ketamine in patients with chronic nonmalignant pain.
This researchers studied whether implantable peripheral nerve stimulation is a viable option for treating intractable trigeminal neuropathic pain.
The purpose of this study was to investigate why patients treated with antiepileptic drugs experience cognitive impairment and difficulty with activities of daily living.
Researchers to explore the somatosensory changes related to trigeminal nerve damage using psychophysical and electrophysiological tools.
Computed tomography-guided pulsed radiofrequency therapy may offer pain relief, improve quality of life, and reduce medication use in patients with trigeminal postherpetic neuralgia.
The injection of onabotulinumtoxinA toward the sphenopalatine ganglion in patients with trigeminal neuralgia may not reduce the number of attacks.
Patients with V3 trigeminal neuralgia may get greater benefit from bipolar vs unipolar radiofrequency thermocoagulation.
An examination of treatment patterns among patients with trigeminal neuralgia suggests that this orofacial disorder appears to be significantly burdensome.
Microvascular decompression for trigeminal neuralgia, hemifacial spasm, and glossopharyngeal neuralgia was found to be a largely safe procedure.
